ENTROPY NEURODYNAMICS LIMITED — Share Issue/Capital Change 2020

Dec 1, 2020

==> picture [595 x 80] intentionally omitted <==

ASX ANNOUNCEMENT

2 December 2020

Notice under Section 708A(5)(E) of the Corporations Act 2001 (Cth)

Exopharm Limited (ASX: EX1) (“Exopharm”, or the “Company”) has today issued 200,000 Fully Paid Ordinary Shares to the Company’s Managing Director and CEO, Dr Ian Dixon, following shareholder approval at the Company’s AGM on 30 November 2020.

Exopharm gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

• 1 The aforementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

• 2 As at the date of this notice, the Company has complied with:

  • (a) The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and (b) Section 674 of the Corporations Act.

• 3 As at the date of this notice, there is no information that is “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

This announcement has been approved for release by the Board.

Sinead Teague Company Secretary Exopharm Limited

EXOPHARM LIMITED ACN: 163 765 991 ASX:EX1 Address: Level 17, 31 Queen Street Melbourne 3000 Telephone: 03 9111 0026 Email: info@exopharm.com Web: www.exopharm.com